These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

807 related items for PubMed ID: 8704686

  • 1. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [Abstract] [Full Text] [Related]

  • 3. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
    Vogelsang G, Bitton R, Piantadosi S, Altomonte V, Horn T, Jones R, Miller C, Marcellus D, Abrams R, Hess A.
    Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
    [Abstract] [Full Text] [Related]

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 5. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA.
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood.
    Gruhn B, Häfer R, Kosmehl H, Fuchs D, Zintl F.
    Bone Marrow Transplant; 1998 May; 21(9):901-7. PubMed ID: 9613782
    [Abstract] [Full Text] [Related]

  • 7. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia.
    Talbot DC, Powles RL, Sloane JP, Rose J, Treleaven J, Aboud H, Helenglass G, Parikh P, Smith C, Rowley M.
    Bone Marrow Transplant; 1990 Jul; 6(1):17-20. PubMed ID: 2202461
    [Abstract] [Full Text] [Related]

  • 9. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 10. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
    Stein M, Feldman E, Seiter K, Chiao JW, Goff H, Baskind P, Beer M, Ahmed T.
    Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
    [Abstract] [Full Text] [Related]

  • 11. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia.
    Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD, Santos GW.
    Blood; 1992 Jun 01; 79(11):3031-5. PubMed ID: 1586747
    [Abstract] [Full Text] [Related]

  • 12. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
    Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico JL, Stoppa AM, Payen C, Marit G, Bouabdallah R, Sotto JJ, Rossi JF, Brandely M, Hercend T, Maraninchi D.
    Eur Cytokine Netw; 2000 Mar 01; 11(1):91-8. PubMed ID: 10705305
    [Abstract] [Full Text] [Related]

  • 13. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, Personeni A, Bellavita P, Rodeghiero F, Barbui T.
    Haematologica; 1998 Jul 01; 83(7):627-35. PubMed ID: 9718868
    [Abstract] [Full Text] [Related]

  • 14. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G, Beguin Y.
    Br J Haematol; 2000 Dec 01; 111(3):745-53. PubMed ID: 11122133
    [Abstract] [Full Text] [Related]

  • 15. Skin biopsy in allogeneic and autologous bone marrow transplant patients: a histologic and immunohistochemical study and review of the literature.
    Esteban JM, Somlo G.
    Mod Pathol; 1995 Jan 01; 8(1):59-64. PubMed ID: 7731943
    [Abstract] [Full Text] [Related]

  • 16. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ, Thompson JS, Jennings CD, Brown SA.
    Transplantation; 1995 Oct 27; 60(8):821-7. PubMed ID: 7482742
    [Abstract] [Full Text] [Related]

  • 17. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
    Tomás JF, Gómez-García de Soria V, Pinilla I, Lamana M, Figuera A, Arranz R, Cámara R, Fernández-Villalta MJ, Alegre A, Fernández-Rañada JM.
    Med Clin (Barc); 1997 Feb 15; 108(6):201-6. PubMed ID: 9102484
    [Abstract] [Full Text] [Related]

  • 18. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
    Klingemann HG, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepherd JD, Sutherland HJ, Phillips GL.
    Bone Marrow Transplant; 1994 Sep 15; 14(3):389-96. PubMed ID: 7994260
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B, Majolino I, Dreger P, Scimè R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N.
    Bone Marrow Transplant; 1997 Oct 15; 20(7):533-41. PubMed ID: 9337054
    [Abstract] [Full Text] [Related]

  • 20. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar 15; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.